Artificial intelligence investment has reached $700 billion globally, according to a new analysis from BCC Research, with intensifying competition between regional markets and a tightening web of regulatory frameworks — including the EU AI Act — shaping how industries deploy the technology. While the report spans sectors broadly, its implications for functional foods and nutraceutical manufacturers are increasingly difficult to ignore, as AI-driven tools embed themselves into ingredient sourcing, clinical-trial design, and quality assurance workflows.
For finished-formulation developers and ingredient suppliers, AI applications range from predictive bioavailability modeling and standardized-extract quality screening to automated structure-function claim substantiation reviews. Machine-learning platforms are now being piloted to flag NDI (New Dietary Ingredient) notification gaps before submissions reach FDA, and to monitor post-market adverse-event data at scale — a capability that has drawn interest from both large contract manufacturers and white-label operators looking to de-risk product launches.
The regulatory dimension is particularly salient. The EU AI Act introduces tiered risk classifications that could directly affect AI tools used in health-claim substantiation, clinical-endpoint analysis, or consumer-facing recommendation engines. Nutraceutical brands selling into European markets will need to assess whether their AI-assisted compliance and labeling workflows fall under the Act's high-risk or limited-risk categories — a determination that may require third-party auditing and documentation trails analogous to those already required for QPS (qualified presumption of safety) dossiers under EFSA review. Operators building regulatory-compliance stacks for supplement lines should treat AI governance as an emerging layer of that infrastructure.
Market context reinforces the urgency. The global nutraceuticals market is on a multi-year growth trajectory, and brands competing on ingredient transparency, clinical backing, and supply-chain integrity are increasingly turning to AI to manage complexity that manual processes cannot absorb. Co-manufacturing partners and ingredient distributors are also investing in AI-enabled traceability systems, a development that aligns with FDA's push for end-to-end supply-chain documentation under current good manufacturing practice (cGMP) rules. Coverage of AI-enabled ingredient traceability trends underscores how quickly this infrastructure layer is maturing.
Operator commentary from formulation consultants suggests the $700 billion investment figure, while headline-grabbing, masks a wide dispersion of deployment maturity. Early adopters in the functional foods space — particularly those with in-house R&D teams running double-blind, placebo-controlled trials — are extracting measurable efficiencies in data analysis and regulatory documentation. Smaller brands, however, face a capability gap that third-party AI-as-a-service providers are moving to fill. How the EU AI Act's compliance clock interacts with that vendor ecosystem will be a defining industry question through 2027. Functional News is part of the Food & Beverage Magazine network.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.